NK-001 (OT-C001)
Cancer (in combination with monoclonal antibodies, e.g., Rituximab)
Phase 1Active
Key Facts
Indication
Cancer (in combination with monoclonal antibodies, e.g., Rituximab)
Phase
Phase 1
Status
Active
Company
About Emercell
Emercell is a Paris-based biotech developing NK-001, an off-the-shelf, allogeneic Natural Killer (NK) cell therapy for oncology. The therapy is produced from pooled umbilical cord blood using a patented process and is intended for synergistic use with existing monoclonal antibodies. The company has achieved significant milestones, including IMPD approval to start a clinical trial in 2025, strategic manufacturing partnerships, and selection for the French government's France 2030 initiative, positioning it in the competitive cell therapy landscape with a potentially more accessible product.
View full company profile